Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 18;28(3):441.
doi: 10.3892/ol.2024.14574. eCollection 2024 Sep.

Ovarian cancer: Diagnosis and treatment strategies (Review)

Xuejiao Li  1 , Zhuocheng Li  1 , Huiling Ma  1 , Xinwei Li  1 , Hongxiao Zhai  1 , Xixi Li  2 , Xiaofei Cheng  1 , Xiaohui Zhao  1 , Zhilong Zhao  1 , Zhenhua Hao  1
Affiliations
Review

Ovarian cancer: Diagnosis and treatment strategies (Review)

Xuejiao Li et al. Oncol Lett. .

Abstract

Ovarian cancer is a malignant tumor that seriously endangers health. Early ovarian cancer symptoms are frequently challenging to detect, resulting in a large proportion of patients reaching an advanced stage when diagnosed. Conventional diagnosis relies heavily on serum biomarkers and pathological examination, but their sensitivity and specificity require improvement. Targeted therapy inhibits tumor growth by targeting certain characteristics of tumor cells, such as signaling pathways and gene mutations. However, the effectiveness of targeted therapy varies among individuals due to differences in their unique biological characteristics and requires individualized strategies. Immunotherapy is a promising treatment for ovarian cancer due to its long-lasting antitumor effect. Nevertheless, issues such as variable efficacy, immune-associated adverse effects and drug resistance remain to be resolved. The present review discusses the diagnostic strategies, rationale, treatment strategies and prospects of targeted therapy and immunotherapy for ovarian cancer.

Keywords: diagnosis; genetic diagnosis; immuno-therapy; ovarian cancer; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Similar articles

See all similar articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Freimund AE, Beach JA, Christie EL, Bowtell DDL. Mechanisms of drug resistance in high-grade serous ovarian cancer. Hematol Oncol Clin North Am. 2018;32:983–996. doi: 10.1016/j.hoc.2018.07.007. - DOI - PubMed
    1. Borch TH, Andersen R, Ellebaek E, Met Ö, Donia M, Svane IM. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. J Immunother Cancer. 2020;8:e000668. doi: 10.1136/jitc-2020-000668. - DOI - PMC - PubMed
    1. Zhang W, Shi F, Kong Y, Li Y, Sheng C, Wang S, Wang Q. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer. Cancer Med. 2022;11:676–691. doi: 10.1002/cam4.4472. - DOI - PMC - PubMed
    1. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345–1356. doi: 10.1038/s41591-021-01450-2. - DOI - PubMed

Grants and funding

The present study was supported by the Henan Science and Technology Research Project (grant no. 232102310318) and the Excellent Young Teachers Training Program of Sanquan College of Xinxiang Medical University (grant nos. SQ2021YQJH02 and SQ2022YQJH01).

LinkOut - more resources